Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2016
At a glance
- Drugs LU AF-35700 (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Lundbeck A/S
- 07 Jun 2017 Biomarkers information updated
- 18 Feb 2016 Last checked against ClinicalTrials.gov record.
- 12 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.